Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.34 USD | +4.48% |
|
+13.09% | -45.87% |
Jul. 01 | Tourmaline Bio, Inc.(NasdaqGS:TRML) added to Russell Small Cap Comp Value Index | CI |
Jul. 01 | Tourmaline Bio, Inc.(NasdaqGS:TRML) added to Russell Small Cap Completeness Index | CI |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 532.4 | 352.1 | - | - |
Enterprise Value (EV) 1 | 532.4 | 41.43 | -77.57 | 34.63 |
P/E ratio | -2.95 x | -4.6 x | -4.3 x | -3.67 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | 35.2 x | 29.3 x |
EV / Revenue | - | - | -7.76 x | 2.89 x |
EV / EBITDA | - | - | - | - |
EV / FCF | - | -0.59 x | 1.11 x | -0.54 x |
FCF Yield | - | -169% | 90.2% | -185% |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 20,337 | 25,647 | - | - |
Reference price 2 | 26.18 | 13.73 | 13.73 | 13.73 |
Announcement Date | 3/19/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | 10 | 12 |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -45.41 | -80.11 | -91.93 | -111.3 |
Operating Margin | - | - | - | -919.28% | -927.55% |
Earnings before Tax (EBT) 1 | - | -42.12 | -78.07 | -109.8 | -121.5 |
Net income 1 | -19.7 | -42.12 | -73.3 | -91.17 | -112.3 |
Net margin | - | - | - | -911.68% | -935.7% |
EPS 2 | -1.790 | -8.870 | -2.986 | -3.192 | -3.738 |
Free Cash Flow 1 | - | - | -70 | -70 | -64 |
FCF margin | - | - | - | -700% | -533.33% |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 7/20/23 | 3/19/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -8.932 | -14.89 | -17.52 | -19.43 | -20.66 | -22.59 | -20.3 | -21.99 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -7.015 | -12.9 | -13.31 | -19.82 | -21.13 | -24.25 | -20.3 | -21.99 |
Net income 1 | -7.015 | -12.9 | -13.31 | -18.37 | -19.44 | -21.57 | -20.3 | -21.99 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -1.640 | -0.8100 | -0.5500 | -0.7220 | -0.7640 | -0.8400 | -0.8300 | -0.9000 |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 11/14/23 | 3/19/24 | 5/13/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | - | - | 311 | 430 | 318 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | - | -70 | -70 | -64 |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | -5.920 | - | - | - |
Capex 1 | - | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 7/20/23 | 3/19/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.56% | 352M | |
+20.82% | 127B | |
+21.96% | 116B | |
+25.30% | 27.69B | |
-22.97% | 19.62B | |
-18.10% | 16.26B | |
-19.03% | 15.49B | |
+11.66% | 14.81B | |
-48.41% | 14.39B | |
+54.78% | 14.11B |
- Stock Market
- Equities
- TRML Stock
- Financials Tourmaline Bio, Inc.